1. A CASE CHALLENGE IN HFrEF:

2. Case Study:

3. Case Study (cont)

4. Case Study: What Is the Next Step?

5. Stepwise Treatment for Symptomatic Patients With HF – NYHA II-IV

6. MRAs: Mechanism of Action

7. MRAs in HF

8. PARADIGM-HF Primary Results: Significant Reduction in Primary Endpoints, CV Death, and All-Cause Mortality

9. ESC Guidelines for HF: Therapeutic Algorithm for a Patient With Symptomatic HFrEF

10. RALES: Mortality Reduction With Spironolactone

11. PARADIGM-HF: Treatment Regimens

12. Gynecomastia With MRA Use in HF

13. Pathways Blocked by Pharmacological Therapies in HF

14. PARADIGM HF: Adverse Events With Sacubitril/Valsartan

15. PARADIGM- HF: Hyperkalemia With MRA Use -- Less Risk With Sacubitril/Valsartan

16. ESC Guidelines for HF: Pharmacological Treatments in Symptomatic (NYHA Class II-IV) HFrEF: Target Dosing

17. Early Benefit of Sacubitril/Valsartan

18. HF: A Lethal Progressive Disease

19. When Starting Sacubitril-Valsartan:

20. Abbreviations

21. Abbreviations (cont)